In this study, for the first time we revealed a significant decrease in BDNF levels after ECT sessions in acute manic patients. Besides clinical remission after treatment in acute mania, the decrement in BDNF levels does not seem to be related to clinical response. Thus cumulative effects of mood episodes for the ongoing decrease in BDNF levels might be borne in mind despite the achievement of remission and/or more time being required for an increase in BDNF levels after treatment.

No abstract

ÖZET: Lityunn monoterapisi alan bipolar bozukluk hastalarinda nnetabolik sendrom parametrelerinin yayginligi Amaf: Bipolar bozuklukta atipik antipsikotik, duygudurum düzenleyicileri ya da kombine ilaç kullanimi ve geçirilmij depresif dönemler metabolik sendromdan sorumlu tutulmaktadir. Lityum monoterapisinin kilo alimi ile ili;kili oldugunu bildiren yayinlar olmasina kar;in, metabolik sendrom ile ilijkisini arajtiran yayina rastlanmamijtir. Bu çalijmada, lityum monoterapisi alan, ötimik bipolar bozukluk hastalarinda metabolik sendrom yayginliginin ara^tirilmasi amaçlanmiçtir. Yöntem: Ötimik ve lityum monoterapisi altinda olan hastalarin Ocak 2009 ve Ocak 2011 tarihieri arasindaki dosya bilgileri taranmiçtir. NCEP ATP III ölcütlerine göre metabolik sendrom parametreleri olan; trigliserid, yiiksek dansiteli lipoprotein, açlik kan jekeri, bel çevresi ve tansiyon bilejenleri kaydedilmlçtir. En az uç aydir lityum monoterapisi kullanan hasta dosyalarinin verileri çali;maya alindi. Son uç ay içinde lityum di;inda bajka psikotrop ilaç kullanmij, ardindan lityum monoterapisine geçilmi; ya da beraberinde aikol madde kullaninni bildirilmi; hasta dosyalari çaliçma di^inda tutulmu^tur. Bulgular: Hastalarin ya; ortalamasi 40.47±11.41; kadinlarin yaj ortalamasi 41.84±12.49 ve erkekierin yas ortalamasi ise 38.88±9.61 (p=0.313) idi. Ilk atak tipine bakildigmda hastalarin 34'ü depresif, 29'u manik ve ikisinin karma atak ya;ami$ olduklari görüldü. Hastalarin hastalik siireleri 16.70±9.86 ve tedavi süreleri 16.67±9.90 yil idi. Hastalarin kullandigi ortalama lityum dozu 1160±274 mg/gün ve ortalama kan düzeyleri 0.761±0.141 mEq/l idi. Lityum kullanma süresi 156.29±117.53 hafta idi. Hastalarin ortalama BKl 27.67±4.47 kg/m' ve bel çevresi 87.72±12.48 cm idi ve cinsiyetler arasinda BKl ve bel çevresi bakimindan anlamli bir fark yoktu (p=0.173 ve p=0.434, sirasiyla). Ortalama açlik kan jekeri düzeyi 87.86±15.53 mg/dl, total kolesterol düzeyi 180.29±47.38 mg/dl; HDt düzeyi 38.81±8.62 mg/dl; trigliserid düzeyi 136.571108.08 mg/dl idi. Kesitsel olarak metabolik sendrom tani ölcütünü kar;ilayan hasta sayisi on idi. Bu on hastanm dokuzu kadin, biri erkekti (xM.841, p=0.028). Sonuç: Bipolar bozukluk olgularinda, lityum monoterapisi ile metabolik sendrom gelijme olasiligi diger tedavilere göre daha düjük gibi görünmektedir. Lityum monoterapisinin kilo alimina yol açabilecegi, yine de diabet mellitusu ve bipolar bozukiugu olan hastalarda kan jekeri açisindan olumiu olabilecegi düjünülebilir. Lityum monoterapisi ve metabolik sendrom arasindaki iliçkinin anla;ilabilmesi için detayli, ileriye dönük ve geni; örneklemli çalijmalargereklidir. Anahtar sözcükler: Abdominal obezite metabolik sendrom, lityum monoterapisi, vücut kitle indeksi Klinik Psikofarmakoloji BUIteni 2012;22(4):320-4 ABSTRACT:

No abstract

Aim: Oxidative stress is defined as exposure to excessive oxidants and/or decrease in antioxidant capacity. Several studies have shown the effects of free radicals and antioxidant defense systems in bipolar disorder. We aimed to investigate the role of thioredoxin (TRX), which is a novel oxidative stress marker in patients with bipolar disorder.Methods: Sixty-eight hospitalized bipolar patients who were in manic episode were included in the study. As a control group, 30 healthy people were elected. Two groups were formed. The first group consisted of patients who were undergoing electroconvulsive treatment + antipsychotic treatment (haloperidol+quetiapine) and members of the other group were taking only antipsychotic treatment. Plasma thioredoxin levels were measured before and after treatment.Results: Pretreatment plasma TRX levels of patients were significantly lower than the controls (P < 0.05). Comparing pre-and post-treatment plasma TRX levels of all patients, post-treatment plasma TRX levels were significantly lower than the pre-treatment plasma TRX levels (P < 0.05). When we compared TRX levels between the electroconvulsive treatment + antipsychotic treatment group and the antipsychotic treatment group (P > 0.05) and within groups (P > 0.05) we did not find any statistically significant difference. Conclusion:Oxidative balance is impaired in bipolar disorder manic episode in favor of the oxidants. Decreased plasma TRX levels in the manic episode probably mean that antioxidant capacity is decreased in the bipolar disorder patients in the manic episode. Further studies in euthymic and depressive states are also needed to gain more insight into the role of TRX in bipolar disorder.

No abstract

Objective: Peroxisome proliferator-activated receptors (PPARs) are a group of nuclear receptor family providing the modulation of the genes having a role in gluco-lipid metabolism and inflammation. Here, we aimed to compare serum PPARγ levels between medication-free schizophrenia patients and healthy controls. Methods: Forty-five inpatients with schizophrenia and 39 healthy controls were included in the study. Serum PPARγ levels and metabolic syndrome (MetS) parameters of the patients and controls were compared. Results: There were no statistically significant differences between the patients (1.42 ± 0.64 ng/ ml) and the control group (1.59 ± 1.10 ng/ml) in terms of serum PPARγ levels. No statistically significant correlations were determined between the MetS parameters and PPARγ levels. Conclusions: Our findings showed that PPARγ, which we predicted to have a role in metabolic disorders and inflammatory process in schizophrenia, did not seem to have a role in the acute exacerbation of schizophrenia.ARTICLE HISTORY

No abstract